AGEN · XBRL financial data

Agenus financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	88	296	98	156	103	114
Cost of revenue	2	3	11	3	0	1
Research and development	143	179	187	235	156	79
General and administrative	59	76	81	79	72	54
Operating income (loss)	(117)	26	(179)	(160)	(120)	(20)
Interest income	—	—	2	6	3	0
Interest expense	—	—	64	104	120	56
Other income (expense)	—	—	11	0	6	72
Income tax expense (benefit)	0	0	0	0	0	0
Earnings per share, basic USD per share	(1.05)	(0.11)	(0.78)	(0.69)	(10.59)	0.00
Earnings per share, diluted USD per share	(1.05)	(0.11)	(0.78)	(0.69)	(10.59)	0.00
Weighted average shares, basic millions of shares	0	0	0	0	21	30
Weighted average shares, diluted millions of shares	0	0	0	0	21	30

† Share count changed about 1/17 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (AGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	100	292	179	76	40	3
Short-term investments	—	15	15	—	—	—
Accounts receivable	1	2	3	26	0	2
Total current assets	114	332	213	112	46	133
Property and equipment, net	27	60	133	133	120	15
Right-of-use asset	33	31	31	30	27	8
Goodwill	25	25	25	25	24	24
Total assets	215	466	414	314	226	227
Accounts payable	17	30	41	61	61	83
Accrued liabilities	29	42	38	45	35	34
Current portion of long-term debt	1	1	1	0	3	45
Total current liabilities	130	157	189	256	221	323
Long-term debt	19	13	13	13	30	0
Lease liability, non-current	34	42	63	63	55	10
Accumulated deficit	(1,466)	(1,490)	(1,710)	(1,956)	(2,183)	(2,183)
Total stockholders' equity	(204)	34	(61)	(160)	(326)	(271)
Total liabilities and equity	215	466	414	314	226	227
Common shares outstanding (cover page) millions of shares	205	257	333	419	25	38

† Share count changed about 1/17 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (AGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	10	20	18	23	17	14
Net cash from operating activities	(139)	10	(175)	(224)	(158)	(77)
Purchases of property and equipment	3	34	53	10	1	0
Net cash from investing activities	(4)	(43)	(34)	3	0	1
Proceeds from issuing equity	176	198	99	133	33	36
Proceeds from long-term debt	6	—	—	—	—	—
Repayments of long-term debt	—	—	—	—	—	3
Net cash from financing activities	184	225	96	120	123	37
Net change in cash	41	192	(113)	(102)	(36)	(39)

† Share count changed about 1/17 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Agenus	19	35	(31)*	45.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Vistagen Therapeutics	17	not reported	(15)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Skye Bioscience	8.1	not reported	(7.1)*	35.4M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	36	3.2	(26)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6.8	not reported	(23)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	37	57	1.6*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Neurogene	112	not reported	(24)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19	1.6	(20)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41	6.1	(6.9)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.